{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:34:41Z","timestamp":1786995281504,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.ophtha.2006.02.027","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T09:09:41Z","timestamp":1146647381000},"page":"992-1001.e6","source":"Crossref","is-referenced-by-count":188,"title":["Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"113","author":[{"given":"Donald J.","family":"D\u2019Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2006.02.027_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2006.02.027_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archopht.1994.01090230090028","article-title":"Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor\u2013like activity in proliferative diabetic retinopathy","volume":"112","author":"Malecaze","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib4","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2006.02.027_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib6","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2006.02.027_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti\u2013vascular endothelial growth factor antibody fragment","volume":"120","author":"Krzystolik","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-9394(01)01381-2","article-title":"Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate","volume":"133","author":"Tolentino","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","article-title":"Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate","volume":"114","author":"Tolentino","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0002-9440(10)64063-1","article-title":"Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium","volume":"158","author":"Schwesinger","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib12","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archopht.121.11.1621","article-title":"Potential public health impact of Age-Related Eye Disease Study results","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib14","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2006.02.027_bib15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2006.02.027_bib17","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib19","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2006.02.027_bib21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2006.02.027_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration","volume":"131","year":"2001","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642006002879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642006002879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T16:20:16Z","timestamp":1547655616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642006002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0161642006002879"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2006.02.027","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}